Roques B P, Lucas-Soroca E, Chaillet P, Costentin J, Fournié-Zaluski M C
Proc Natl Acad Sci U S A. 1983 Jun;80(11):3178-82. doi: 10.1073/pnas.80.11.3178.
Thiorphan, N-[(R,S)-3-mercapto-2-benzylpropanoyl]glycine is a highly potent inhibitor (Ki = 3.5 nM) of "enkephalinase," a metalloendopeptidase cleaving the Gly-Phe bond (positions 3 and 4) of enkephalins in brain tissue. In accordance with this property, thiorphan displays antinociceptive activity after systemic administration. However, thiorphan also inhibits to a lesser extent (Ki = 140 nM) the widely distributed angiotensin-converting enzyme, a carboxydipeptidase implicated in blood pressure regulation. Therefore, in view of an eventual clinical use of enkephalinase inhibitors, it was very important to develop fully specific compounds. Such derivatives were obtained taking into account that N-methylation of the ultimate amide bond of dipeptides strongly decreases enkephalinase affinity without affecting angiotension-converting enzyme recognition, whereas retro-inversion of the amide bond leads to the inverse effect. Thus, the retro-inverso dipeptide (R)-H2N-CH(CH2 phi)-NHCO-CH2-CO2H exhibits an inhibitory potency on enkephalinase (IC50 approximately equal to 12 muM) close to that of the natural dipeptide L-Phe-Gly (IC50 approximately equal to 3 muM). This result shows the topological analogy between the crucial components involved in enkephalinase recognition both in active dipeptides and structurally related retro-inverso isomers. Taking into account these observations, retro-thiorphan, (R,S)-HS-CH2-CH-(CH2 phi)-NHCO-CH2-COOH, was prepared. As compared to thiorphan, the retro isomer is 50% as potent (Ki = 6 nM) on enkephalinase but displays a drastic loss of potency on angiotension-converting enzyme (IC50 greater than 10,000 nM). This specificity was interpreted as a consequence of differences in the stereochemical constraints involving enzyme-inhibitor hydrogen bonding. This hypothesis is supported by reported crystallographic studies on related enzymes such as thermolysin and carboxypeptidase A. As expected, retro-thiorphan exhibits about the same analgesic potency as thiorphan on the hot plate and writhing tests in mice. Therefore, the topological concept of retro-inverso isomers could be extended to other enkephalinase inhibitors, allowing the design of potent and highly selective compounds occurring as new classes of analgesic and psychoactive agents.
硫喷妥,N-[(R,S)-3-巯基-2-苄基丙酰基]甘氨酸是一种高效的“脑啡肽酶”抑制剂(Ki = 3.5 nM),脑啡肽酶是一种金属内肽酶,可切割脑组织中脑啡肽的Gly-Phe键(第3和第4位)。基于这一特性,硫喷妥全身给药后表现出抗伤害感受活性。然而,硫喷妥对广泛分布的血管紧张素转换酶(一种参与血压调节的羧基二肽酶)的抑制作用较小(Ki = 140 nM)。因此,鉴于脑啡肽酶抑制剂最终可能用于临床,开发完全特异性的化合物非常重要。考虑到二肽末端酰胺键的N-甲基化会强烈降低脑啡肽酶亲和力而不影响血管紧张素转换酶的识别,而酰胺键的反向转化则会产生相反的效果,从而获得了此类衍生物。因此,反向二肽(R)-H2N-CH(CH2苯环)-NHCO-CH2-CO2H对脑啡肽酶的抑制效力(IC50约为12 μM)与天然二肽L-Phe-Gly(IC50约为3 μM)相近。这一结果表明,在活性二肽和结构相关的反向异构体中,参与脑啡肽酶识别的关键成分之间存在拓扑相似性。基于这些观察结果,制备了反向硫喷妥,(R,S)-HS-CH2-CH-(CH2苯环)-NHCO-CH2-COOH。与硫喷妥相比,反向异构体对脑啡肽酶的效力为其50%(Ki = 6 nM),但对血管紧张素转换酶的效力急剧丧失(IC50大于10,000 nM)。这种特异性被解释为酶-抑制剂氢键立体化学限制差异的结果。这一假设得到了对诸如嗜热菌蛋白酶和羧肽酶A等相关酶的晶体学研究报道的支持。正如预期的那样,反向硫喷妥在小鼠热板和扭体试验中的镇痛效力与硫喷妥大致相同。因此,反向异构体的拓扑概念可以扩展到其他脑啡肽酶抑制剂,从而设计出作为新型镇痛和精神活性药物的强效且高度选择性的化合物。